KRAS and neoplasm: Evaluating co-occurring mutations depending on PD-L1 status, in PD-L1 negative tumours, KRAS/STK11 mutation was detected in 10% and STK11/KEAP1 mutation in 6% of cases, which was consistent with previous clinical study results.